Susoctocog alfa
| Clinical data | |
|---|---|
| Trade names | Obizur |
| Other names | Antihemophilic factor (recombinant) |
| AHFS/Drugs.com | Monograph |
| License data | |
| Drug class | Antihemophilic factor |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| DrugBank | |
| UNII | |
Susoctocog alfa, sold under the brand name Obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor VIII.[2][3]
Susoctocog alfa was approved for medical use in the United States in October 2014,[4][5] and for medical use in the European Union in November 2015.[2]
Factor VIII is one of the proteins needed for normal clotting of the blood.[2]
References
- ^ "Antihemophilic factor Use During Pregnancy". Drugs.com. 20 January 2020. Retrieved 6 March 2020.
- ^ a b c "Obizur EPAR". European Medicines Agency. 6 March 2020. Retrieved 6 March 2020.
- ^ "Obizur (antihemophilic factor- recombinant, porcine sequence kit". DailyMed. 2 January 2020. Retrieved 6 March 2020.
- ^ "Obizur". U.S. Food and Drug Administration (FDA). 13 March 2018. Archived from the original on 23 April 2019. Retrieved 6 March 2020.
- ^ "Obizur". U.S. Food and Drug Administration (FDA). 27 September 2019. STN: BL 125512. Retrieved 6 March 2020.
External links
- "Susoctocog alfa". Drug Information Portal. U.S. National Library of Medicine.
 | This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |